Results 21 to 30 of about 761 (100)

Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis

BMJ Open Gastroenterology
Objective Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC).
Xiang Guo, Peter M Irving, Laurent Peyrin-Biroulet, Séverine Vermeire, Joseph Wu, Irene Modesto, Marla C Dubinsky, Andres J Yarur, Miguel Regueiro, Martina Goetsch, Krisztina Lazin, Guibao Gu, Aoibhinn McDonnell, Jesse Green, Alexis B Dalam   +14 more
doaj   +2 more sources

Development and validation of stability-indicating method of etrasimod by HPLC/DAD/MS/MS technique with greenness profiling

Heliyon
Etrasimod, a novel selective sphingosine-1-phosphate receptor modulator, was recently approved by the U.S. Food and Drug Administration and the European Medicinal Agency for the treatment of moderately to severely active ulcerative colitis in adults.
Jelena Kovačić, Daniela Amidžić Klarić, Nikša Turk, Željko Krznarić, Ana Mornar   +4 more
doaj   +2 more sources

Advances in the Management of Pediatric Inflammatory Bowel Disease: From Biologics to Small Molecules [PDF]

Pharmaceuticals
Background: The management of pediatric inflammatory bowel disease (PIBD) has evolved significantly over the past two decades, transitioning from corticosteroids and immunomodulators to biologic and small-molecule therapies. These advances have aimed not
Benedetta Mucci, Elisabetta Palazzolo, Flaminia Ruberti, Lorenzo Ientile, Marco Natale, Susanna Esposito   +5 more
doaj   +2 more sources

Safety of ozanimod and etrasimod in ulcerative colitis: A disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System database. [PDF]

Medicine (Baltimore)
Ozanimod and etrasimod are sphingosine-1-phosphate receptor modulators approved for ulcerative colitis treatment.
Chen L, Wan D, Xing B, Ji X, Zhou W, Liu Y, Lu Y.   +6 more
europepmc   +2 more sources

Beyond the Colon: Acute Hemolysis Associated With Etrasimod Therapy. [PDF]

Cureus
Etrasimod is an oral sphingosine 1-phosphate (S1P) receptor modulator used in the treatment of moderately to severely active ulcerative colitis (UC). Although its safety profile has been described in clinical studies, hematologic complications remain ...
Ahmed S, Khan S, Vargas Carranza E, Mumtaz SU, Delzoppo M.   +4 more
europepmc   +2 more sources

Modulating sphingosine 1-phosphate receptor signaling skews intrahepatic leukocytes and attenuates murine nonalcoholic steatohepatitis

Frontiers in Immunology, 2023
Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid associated with nonalcoholic steatohepatitis (NASH). Immune cell-driven inflammation is a key determinant of NASH progression.
Chieh-Yu Liao, Fanta Barrow, Nanditha Venkatesan, Yasuhiko Nakao, Amy S. Mauer, Gavin Fredrickson, Myeong Jun Song, Myeong Jun Song, Tejasav S. Sehrawat, Debanjali Dasgupta, Rondell P. Graham, Xavier S. Revelo, Harmeet Malhi   +12 more
doaj   +1 more source

Bowel urgency in ulcerative colitis is associated with clinical endpoints, health-related quality of life, and biomarkers: data from the etrasimod ELEVATE UC 52 trial. [PDF]

Crohns Colitis 360
Background Bowel urgency (BU) is a disruptive ulcerative colitis (UC) symptom. Etrasimod, a sphingosine 1-phosphate (S1P)1,4,5 receptor modulator, improved BU in the ELEVATE UC clinical program.
Dubinsky MC, Cohen ER, Irving PM, Goetsch M, Lazin K, Bhattacharjee A, Pradeep G, Hur P, Cognata C, Wosik K, Panaccione R.   +10 more
europepmc   +2 more sources

Etrasimod Treatment Modulates Circulating and Lymph Node-Derived Lymphocytes in Crohn's Disease. [PDF]

Int J Mol Sci
Etrasimod is an oral selective sphingosine-1 phosphate receptor modulator, and its anti-inflammatory mechanism of action in inflammatory bowel diseases is not completely understood.
Nikolakis D, Pruijt MJ, Verhoeff J, de Voogd FAE, Teichert C, Ryan RD, Branquinho D, Crosby C, van de Sande MGH, Grootjans J, D'Haens GR.   +10 more
europepmc   +2 more sources

Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double-blind, placebo-controlled, Phase 2 study. [PDF]

J Eur Acad Dermatol Venereol
BackgroundEtrasimod, an oral, selective sphingosine 1-phosphate 1, 4 and 5 receptor modulator approved for the treatment of ulcerative colitis, has been studied in immune-mediated inflammatory diseases, including alopecia areata (AA).ObjectivesTo ...
King B, Mesinkovska N, Senna M, Luo X, Minkiewicz J, Selfridge A.   +5 more
europepmc   +2 more sources

Sphingosine 1-Phosphate Modulation in Inflammatory Bowel Diseases: Keeping Lymphocytes Out of the Intestine

Biomedicines, 2022
Inflammatory bowel diseases (IBDs) are chronic and disabling conditions that, uncontrolled, lead to irreversible bowel damage and associated comorbidities. Despite the new era of biological therapies, IBDs remain not curative. The treatment purpose is to
Arianna Dal Buono, Roberto Gabbiadini, Ludovico Alfarone, Virginia Solitano, Alessandro Repici, Stefania Vetrano, Antonino Spinelli, Alessandro Armuzzi   +7 more
doaj   +1 more source